92 related articles for article (PubMed ID: 32133644)
21. The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice.
Castor MG; Rezende B; Resende CB; Alessandri AL; Fagundes CT; Sousa LP; Arantes RM; Souza DG; Silva TA; Proudfoot AE; Teixeira MM; Pinho V
J Immunol; 2010 Mar; 184(5):2646-54. PubMed ID: 20100934
[TBL] [Abstract][Full Text] [Related]
22. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses.
Korngold R; Marini JC; de Baca ME; Murphy GF; Giles-Komar J
Biol Blood Marrow Transplant; 2003 May; 9(5):292-303. PubMed ID: 12766879
[TBL] [Abstract][Full Text] [Related]
23. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
[TBL] [Abstract][Full Text] [Related]
24. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
[TBL] [Abstract][Full Text] [Related]
25. IL-35 inhibits acute graft-versus-host disease in a mouse model.
Zhang XH; Zhou Y; Zhang JM; Zhou SY; Wang M; Feng R; Feng FE; Wang QM; Zhu XL; Zhao XS; Lv M; Kong Y; Chang YJ; Huang XJ
Int Immunopharmacol; 2015 Dec; 29(2):383-392. PubMed ID: 26507167
[TBL] [Abstract][Full Text] [Related]
26. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
27. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
28. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
[TBL] [Abstract][Full Text] [Related]
29. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.
Zeiser R; Youssef S; Baker J; Kambham N; Steinman L; Negrin RS
Blood; 2007 Dec; 110(13):4588-98. PubMed ID: 17827390
[TBL] [Abstract][Full Text] [Related]
30. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M
Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
[TBL] [Abstract][Full Text] [Related]
31. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function.
Tang L; Ma S; Gong H; Wang J; Xu Y; Wu D; Sun A
Arch Immunol Ther Exp (Warsz); 2019 Jun; 67(3):179-187. PubMed ID: 30927016
[TBL] [Abstract][Full Text] [Related]
33. Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Zhang R; Wang X; Hong M; Luo T; Zhao M; Shen H; Fang J; Li X; Zang S; Chen P; Nie D; Zheng P; Wu Q; Xia L
Oncotarget; 2017 Apr; 8(14):23360-23375. PubMed ID: 28423578
[TBL] [Abstract][Full Text] [Related]
34. [Effect of bone marrow mesenchymal stem cells on acute graft versus host disease and graft versus leukemia after allogeneic bone marrow transplantation].
Hu WB; Gao QP; Chen YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):404-7. PubMed ID: 15972130
[TBL] [Abstract][Full Text] [Related]
35. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
36.
Gupta SK; Gohil D; Momin MB; Yadav S; Chichra A; Punatar S; Gokarn A; Mirgh S; Jindal N; Nayak L; Hingorani L; Khattry N; Gota V
Cell Transplant; 2024; 33():9636897241226573. PubMed ID: 38258793
[TBL] [Abstract][Full Text] [Related]
37. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
Leshem B; Vourka-Karussis U; Slavin S
Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
[TBL] [Abstract][Full Text] [Related]
38. CXCR3 blockade combined with cyclosporine A alleviates acute graft-versus-host disease by inhibiting alloreactive donor T cell responses in a murine model.
Miao S; Tang B; Liu H; Wang Z; Shi Y; Dong Y; Liu W; Qin C; Ren H
Mol Immunol; 2018 Feb; 94():82-90. PubMed ID: 29288898
[TBL] [Abstract][Full Text] [Related]
39. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
[TBL] [Abstract][Full Text] [Related]
40. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
